血浆前激肽释放酶在血管疾病中的研究进展  

Research Advances on the Plasma Kallikrein in Vascular Disease

作　　者：李慧慧 徐鹏飞[2] 张杰 陈虹 王淼[1,2] LI Hui-hui;XU Peng-fei;ZHANG Jie;CHEN Hong;WANG Miao(College of Chemistry and Life Sciences,Zhejiang Normal University,Jinhua 028000,China;State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]浙江师范大学化学与生命科学学院,金华市321000 [2]中国医学科学院,北京协和医学院,国家心血管病中心,阜外医院,心血管疾病国家重点实验室,北京市100037

出　　处：《中国分子心脏病学杂志》2021年第3期4028-4032,共5页Molecular Cardiology of China

基　　金：国家重点研发计划主动健康和老龄化科技应对重点专项项目(2020YFC2008000);中国医学科学院医学与健康技术创新工程项目(2016-I2M-1-003,2017-I2 M-1-008)。

摘　　要：生物体内,血浆激肽释放酶(kallikrein,Kal)以其无活性的前体-血浆前激肽释放酶(prekallikrein,PK)的形式存在,属于胰蛋白酶样丝氨酸蛋白酶家族。PK参与调控多种生理途径,如凝血途径,纤维蛋白溶解、炎症反应和补体途径等。因此,PK被认为是多种疾病的潜在靶标,包括遗传性血管水肿、糖尿病的微血管并发症、心血管疾病和脑血管疾病。本文总结了PK的分子生物学作用及其在血管疾病发生发展过程中扮演的角色,并讨论了现阶段PK药物的研究进展。In organisms,plasma kallikrein(Kal)exists in the form of its inactive precursor,plasma prekallikrein(PK),and belongs to the trypsin-like serine protease family.PK is involved in the regulation of various physiological pathways,such as the coagulation pathway,fibrinolytic process,inflammation process and the complement pathway.Therefore,PK is considered as a potential target for many diseases,including hereditary angioedema,microvascular complications of diabetes,cardiovascular disease and cerebrovascular disease.This review summarizes the molecular biological role of PK and its role in the occurrence and development of vascular diseases,and discusses the current research status of PK drugs.

关 键 词：前激肽释放酶 凝血途径 遗传学血管性水肿 心血管疾病 

分 类 号：R543[医药卫生—心血管疾病]